Technology ID
TAB-2251

Improved Standard for Immune System Recovery Assay

E-Numbers
E-067-2011-0
Lead Inventor
Douek, Daniel (NIAID)
Co-Inventors
Koup, Richard (NIAID)
Hill, Brenna (NIAID)
Applications
Research Materials
Diagnostics
Therapeutic Areas
Infectious Disease
Development Status
Fully developed
Lead IC
NIAID
ICs
NIAID
Monitoring an immune system that has been depleted by infection (e.g., HIV), chemotherapy, or progenitor cell transplantation is vital to assessing individual’s recovery status. This technology provides a new plasmid standard to be used as part of the existing TREC assay. This new plasmid has a shorter insert than the commercially available one, which means it now matches the PCR product generated in the qPCR reaction in the TREC assay. Additionally, the new plasmid is easier to grow up than the existing standard.
Commercial Applications
  • TREC assay for T cell concentration measurements
Competitive Advantages
  • The insert of standard plasmid is shorter and directly matches the PCR product generated in the qPCR reaction
  • The standard plasmid is easy to grow up

Request More Info

Licensing Contact:
Salata, Carol
csalata@mail.nih.gov

Publications

Collaborations

  • Licensing
Date Published